Jones Financial Companies
NBIX icon

Jones Financial Companies’s Neurocrine Biosciences NBIX Stock Holding History

Jones Financial Companies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.64M Buy
33,495
+10,344
+45% +$1.53M ﹤0.01% 1140
2026
Q1 		$2.97M Buy
23,151
+22,331
+2,723% +$2.96M ﹤0.01% 1270
2025
Q4 		$116K Buy
820
+116
+16% +$16.8K ﹤0.01% 2160
2025
Q3 		$99.9K Buy
704
+104
+17% +$14.1K ﹤0.01% 2090
2025
Q2 		$75.3K Buy
600
+253
+73% +$29K ﹤0.01% 2056
2025
Q1 		$39.3K Buy
347
+161
+87% +$20.4K ﹤0.01% 2158
2024
Q4 		$25.4K Buy
186
+55
+42% +$6.8K ﹤0.01% 2151
2024
Q3 		$15.1K Buy
131
+107
+446% +$14.7K ﹤0.01% 2063
2024
Q2 		$3.3K Buy
+24
New +$3.29K ﹤0.01% 2049
2022
Q3 		– Sell
-13
Closed -$1K – 666
2022
Q2 		$1K Buy
+13
New +$1.2K ﹤0.01% 663
2021
Q2 		– Sell
-6
Closed -$1K – 742
2021
Q1 		$1K Buy
+6
New +$629 ﹤0.01% 768

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jones Financial Companies's NBIX Position: Q2 2026 in Review

Jones Financial Companies increased its Neurocrine Biosciences (NBIX) stake by 45% in Q2 2026, buying an estimated $1.53M and bringing the position to 33,495 shares worth $5.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

Jones Financial Companies first reported a position in NBIX in Q1 2021 and has held it in 11 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Jones Financial Companies held 33,495 shares of Neurocrine Biosciences worth $5.64M as of Q2 2026.
  • Jones Financial Companies bought 10,344 Neurocrine Biosciences shares in Q2 2026, an estimated $1.53M.
  • Neurocrine Biosciences made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #1140 holding.
  • Jones Financial Companies first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 11 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.